Immune Pharmaceuticals Inc

Immune Pharmaceuticals — Investor Presentation (January 2018)

20 slides from Immune Pharmaceuticals's investor presentation, Jan 9, 2018

  1. Slide 1: Immune Pharmaceuticals (NASDAQ: IMNP)

    CONFIDENTIAL Not to be Used or Distributed Without Immune’s Permission IMMUNE PHARMACEUTICALS (NASDAQ: IMNP) Elliot Maza, President & CEO January 10, 2018

  2. Slide 2: Forward Looking Statement

    2 This presentation and oral statements made by representatives of the Company may contain forward - looking statements regarding future events or the future financial performance of the Company . These statements are based on our current expectations and are subject to risks and uncertainties that

  3. Slide 3: Executive Summary

    3 F ocus: immunologic and inflammatory diseases Bertilimumab – Ongoing phase 2 in two indications: fully human , anti - eotaxin - 1 mAb for bullous pemphigoid, ulcerative colitis and other indications NanoCyclo – Late - stage preclinical: nano - encapsulated topical formulation of cyclosporine for a

  4. Slide 4: New Management Focused on Execution

    4 Elliot Maza, JD, CPA, President and CEO ▪ Extensive and successful experience in managing micro - cap biotech and drug manufacturing companies Tony Fiorino, MD, PhD, CMO/COO ▪ Broad experience in leading clinical - stage biotech companies and a former fund manager well - versed in finance John Zha

  5. Slide 5: Clinical Stage Pipeline with Multiple Shots on Goal

    5 Clinical Stage Pipeline with Multiple Shots on Goal Program Indication Preclinical Phase 1 Phase 2 Phase 3 Bertilimumab Bullous Pemphigoid Ongoing Ulcerative Colitis Ongoing Allergic Rhinitis Completed Allergic Conjunctivitis Completed Atopic Dermatitis Phase 2 ready Other inflammatory conditions

  6. Slide 6: Eotaxin-1 Implicated in Many Inflammatory Diseases

    6 6 Gastroenterology Ulcerative Colitis Crohn’s Disease Primary Sclerosing Cholangitis (PSC ) Eosinophilic Esophagitis Re s pi ra tory Asthma Chronic obstructive pulmonary disease (COPD) Opht halmology Vernal Keratoconjunctivitis (VKC) Atopic Keratoconjunctivitis (AKC) Age Related Macular Degenerati

  7. Slide 7: Targeting Eotaxin-1 – A Validated Rationale

    7 Targeting Eotaxin - 1 – A Validated Rationale Eotaxin - 1 is responsible for recruiting eosinophil cells toward sites of injury or inflammation where they release inflammatory substances Targeting eosinophil - related cytokines is a clinically and commercially validated solution ▪ Three antibodies

  8. Slide 8: Bertilimumab – A Novel Approach

    8 Targeting eotaxin - 1 is a distinct and novel approach to modulating eosinophil - mediated inflammation Bertilimumab was initially developed by CAT and we licensed it from Ico Therapeutics Blocks eotaxin - mediated eosinophil migration; active in animal models Over 100 subjects exposed to date: ov

  9. Slide 9: Bertilimumab Clinical Status

    9 Bertilimumab Clinical Status Randomized, placebo - controlled, double - blind (target 42, IV) Mayo Disease Index, mucosal injury Ongoing enrollment 5 Israeli & 6 Russian sites Open - label, single - arm (target 10 - 15, IV) Safety, BPDAI improvement, and steroid reduction Ongoing enrollment 3 Isra

  10. Slide 10: Bullous Pemphigoid

    10 Orphan skin condition that causes large, fluid - filled blisters; most common in people older than 60; severe disease can be life - threatening Estimated 30,000 patients (US and EU) Typically treated with high - dose prednisone tapered over 6 - 12 months Second - line immuno - suppressants such a

  11. Slide 11: Interim Results from Ongoing Phase 2 Study

    11 Interim Results from Ongoing Phase 2 Study Actual Prednisone Dose Expected Prednisone Dose (based on Joly et al , 2002) Subjects received on average 2,555 mg less prednisone

  12. Slide 12: Positive Interim Phase 2 Data

    12 Results from first six of intended 10 - 15 patients 85 % reduction in BPDAI Total Activity Index (p=0.0096) All subjects achieved a >50% improvement; 4/6 with >90% improvement Excellent safety and tolerability of 3 IV bertilimumab doses (days 0 and 14 and 28) Mean initial prednisone dose was just

  13. Slide 13: Inflammatory Bowel Disease (IBD)

    13 Over 3.5 million patients with IBD in the US and EU Patients with moderate to severe disease cycle through biologics such as Remicade ® (infliximab) and Entyvio ® ( vedolizumab ) ▪ Demand for additional treatment options Eotaxin - 1 strongly implicated as a target in IBD ▪ Tissue eotaxin - 1 leve

  14. Slide 14: Ulcerative Colitis Proof-of-Concept Phase 2

    14 Randomized , double - blind, placebo - controlled trial 42 subjects; 2:1 randomization (23 enrolled) Subjects screened for baseline eotaxin - 1 levels 3 IV bertilimumab doses (days 0 and 14 and 28 ) Primary endpoint is clinical response (UC Mayo Clinic Index ) Multiple additional safety and effic

  15. Slide 15: Bertilimumab Development Plans

    15 Complete ongoing clinical trials ▪ BP – end of phase 2 meeting in 2018; will propose single pivotal phase 2/3 registration study ▪ UC – if PoC study positive, will move to larger phase 2b trial Atopic dermatitis ▪ Developing subcutaneous formulation Asthma ▪ Positive animal data ▪ Exploring combi

  16. Slide 16: Bertilimumab Manufacturing

    16 Developed new cell line to produce bertilimumab in a highly efficient and scalable process Process development largely complete Requesting proposals from contract manufacturers Initiation of tech transfer Q2/2018 Will develop subcutaneous formulation in parallel GMP production - ready targeted fo

  17. Slide 17: NanoCyclo – Novel Topical Cyclosporine

    17 Alternatives to topical steroids are highly desired for atopic dermatitis and psoriasis ▪ Topical c alcineurin inhibitors ( Protopic and Elidel ) have a black box warning ▪ Topical cyclosporine never developed because of inadequate skin penetration Our proprietary nano - encapsulated formulation

  18. Slide 18: 2018 Milestones

    18 2018 Milestones Timeline Event Q1 Form 10 filing for Cytovia spin - off Q1 Patent filing for new bertilimumab manufacturing process Q1 - Q2 Complete enrollment and report additional bertilimumab BP data Q2 Begin tech transfer of new manufacturing process to CMO Q2 Launch clinic - enabling NanoCyc

  19. Slide 19: Investment Profile

    19 I nvestment Profile Factor IMNP Broad product pipeline ▪ Bert: More than 13 disease targets ▪ NanoCyclo: Psoriasis and AD Success in clinical trials ▪ Two phase 2 trials ongoing ▪ 2 phase 2 trials completed ▪ Positive interim BP results ▪ Over 100 subjects exposed Timeline to profitability ▪ Bert

  20. Slide 20: Investment Profile

    20 I nvestment Profile Factor IMNP Markets ▪ BP: $500M ▪ UC and others: > $1Bn ▪ NanoCyclo: $500M Competitive Profile ▪ BP: no approved therapy ▪ UC and others: target patients with high eotaxin - 1 ▪ NanoCyclo: safety Market Exclusivity Multiple issued patents with new applications pending and to b

Immune Pharmaceuticals — Investor Presentation (January 2018) on 6ix